| __timestamp | Taro Pharmaceutical Industries Ltd. | Ultragenyx Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 91733000 | 10811000 |
| Thursday, January 1, 2015 | 87644000 | 33001000 |
| Friday, January 1, 2016 | 92365000 | 64936000 |
| Sunday, January 1, 2017 | 85656000 | 99909000 |
| Monday, January 1, 2018 | 88196000 | 127724000 |
| Tuesday, January 1, 2019 | 89971000 | 161524000 |
| Wednesday, January 1, 2020 | 93413000 | 182933000 |
| Friday, January 1, 2021 | 91355000 | 219982000 |
| Saturday, January 1, 2022 | 113676000 | 278139000 |
| Sunday, January 1, 2023 | 198366000 | 309799000 |
| Monday, January 1, 2024 | 218935000 |
In pursuit of knowledge
In the ever-evolving pharmaceutical landscape, understanding the financial dynamics of industry leaders is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Ultragenyx Pharmaceutical Inc. and Taro Pharmaceutical Industries Ltd. over the past decade. From 2014 to 2023, Taro's SG&A costs have shown a steady increase, peaking at approximately 218% of their 2014 levels by 2023. In contrast, Ultragenyx's expenses surged dramatically, reaching nearly 287% of their 2014 figures by 2022, before data became unavailable in 2023. This trend highlights Ultragenyx's aggressive expansion strategy, while Taro maintains a more conservative growth approach. The absence of 2024 data for Ultragenyx suggests a potential shift or reevaluation in their financial strategy. As these companies navigate the complexities of the pharmaceutical market, their SG&A expenses offer a window into their operational priorities and future trajectories.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Sarepta Therapeutics, Inc. vs Ultragenyx Pharmaceutical Inc.
Exelixis, Inc. or Ultragenyx Pharmaceutical Inc.: Who Manages SG&A Costs Better?
Blueprint Medicines Corporation and Ultragenyx Pharmaceutical Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Breaking Down SG&A Expenses: Ultragenyx Pharmaceutical Inc. vs Arrowhead Pharmaceuticals, Inc.
Ultragenyx Pharmaceutical Inc. and Novavax, Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Comparing SG&A Expenses: PTC Therapeutics, Inc. vs Taro Pharmaceutical Industries Ltd. Trends and Insights
Who Optimizes SG&A Costs Better? MorphoSys AG or Taro Pharmaceutical Industries Ltd.
Vericel Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Mesoblast Limited vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends